Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China, shares some insights into a Phase II study evaluating the safety and efficacy of bomedemstat for the treatment of essential thrombocythemia (ET; NCT04254978). Dr Gill first highlights the rationale behind targeting LSD1 in ET, and then discusses the efficacy of this agent, and molecular responses observed in patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
